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Abstract: Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of 
estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite these advances, 
until recently, only docetaxel had been shown to improve survival in patients with castration-resistant disease, and there has been no 
standard treatment options available for men with disease progression on docetaxel. In the last year, cabazitaxel, a novel taxane with 
decreased affinity for ATP-dependent drug efflux pump P-glycoprotein, became the first cytotoxic agent to demonstrate an improvement 
in survival in men with docetaxel-refractory disease, and has received regulatory approval for treatment in this setting. In this review, 
we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and 
direction of future therapeutic investigation.
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Introduction
Prostate  cancer  has  historically  been  considered  a 
chemotherapy-resistant  disease.1,2  However,  over 
the past few decades, with the development of better 
cytotoxic agents and improved trial designs focused 
on clinically relevant endpoints, an important role 
for chemotherapy in the treatment of castration resis-
tant prostate cancer (CRPC) has emerged. Initially, 
estramustine phosphate was approved by the Food 
and Drug Administration (FDA) for the treatment of 
CRPC. However, as a single agent, this drug had lim-
ited activity and notable treatment-related   toxicities. 
The combination of mitoxantrone and prednisone was 
approved by the FDA in the 1990s based on clinical 
trials demonstrating improvements in palliation with 
this  regimen  compared  with    steroids  alone.3  Sub-
sequently, in 2004, docetaxel plus prednisone was 
shown  to  improve  survival  compared  to  mitoxan-
trone and prednisone, in men with CRPC, leading to 
regulatory approval of this regimen.4 In 2010, caba-
zitaxel became the fourth cytotoxic agent approved 
by the FDA for the treatment of CRPC. Herein, we 
will review the preclinical and clinical data support-
ing the development of cabazitaxel for the treatment 
of prostate cancer. We will also discuss the rationale 
for ongoing clinical trials exploring cabazitaxel in 
prostate cancer and other malignancies.
Mechanism of Action
The taxanes act by binding to microtubules, cytoskeletal 
polymers composed of α-tubulin and β-tubulin heterodi-
mers. The binding of taxanes to tubulin promotes the 
stabilization of GDP-bound tubulin in the microtubule 
resulting in inhibition of disassembly and prevention 
of subsequent mitosis and cell   division.5 Derived from 
the bark of yew trees, in 1992, paclitaxel was the first 
taxane approved by the Food and Drug Administration 
(FDA) as an anti-neoplastic agent. Docetaxel, a semi-
synthetic analog with increased potency, was approved 
by the FDA in 1996 for the treatment advanced breast 
cancer and later in 2004 for the treatment of metastatic 
CRPC. These earlier generation taxanes have high sub-
strate affinity for the ATP-dependent drug efflux pump 
P-glycoprotein 1 (P-gp1).6 Therefore, P-gp1 is thought 
to account for, at least in part, both inherent and acquired 
resistance to these agents.
Cabazitaxel,  also  known  as  XRP6258,  is  a 
semi-synthetic taxane from a single diastereoisomer of 
10-deacetyl baccatin III, and derived from the needles 
of various Taxus species. By binding to tubulin, caba-
zitaxel inhibits microtubule depolymerization and cell 
division, resulting in cell cycle arrest. This compound 
was selected for clinical testing due to its poor affinity 
for ATP-dependent drug efflux pump P-gp16,7 and its 
greater blood-brain barrier penetration8 compared to 
paclitaxel and docetaxel. Cabazitaxel has also demon-
strated superior in vitro cytotoxicity compared to doc-
etaxel in several murine and human cancer cell lines.6
phase I clinical experience
A phase I trial evaluated the phamacokinetics and 
safety of administering cabazitaxel at escalating doses 
starting at 10 mg/m2 intravenously every three weeks.9 
Patients  enrolled  on  this  trial  were  allowed  up  to 
two prior treatments (88% with prior chemotherapy, 
and  32%  with  prior  taxane  therapy).  Twenty-five 
patients with advanced solid tumors were enrolled, 
eight of whom had CRPC. Pharmacokinetic param-
eters, including exposure and maximum concentra-
tion, were dose proportional (Table 1). The decline in 
plasma concentrations was best described by a tripha-
sic model; an initial phase with a mean half-life (t1/2) 
of 2.6 minutes, followed by an intermediate phase 
with a mean t1/2 of 1.3 hours, and a prolonged termi-
nal phase with a mean t1/2 of 77.3 hours. No appar-
ent  changes  in  pharmacokinetic  parameters  were 
observed after multiple doses. Cabazitaxel was well 
tolerated at the studied dose levels up to 25 mg/m2,10 
but due to incidence of grade 4 neutropenia observed, 
the recommended phase II dose was 20 mg/m2.
Cabazitaxel is metabolized by the liver, mainly by 
CYP3A4/5 (80%–90%) and to some extent CYP2C8. 
Though formal renal   impairment-pharmacokinetic stud-
ies have not been performed, the presence of mild (CrCl 
50–80  mL/min)  or  moderate  (CrCl  30–50  mL/min) 
renal  impairment  in  the  published  phase  I  study 
did  not  have  a  meaningful  impact  on  exposure  or 
  clearance.    Likewise,  no  formal  hepatic  impairment-
  pharmacokinetic studies have been performed, though 
given the hepatic metabolism of cabazitaxel, altered 
exposure and clearance would be expected.
In the phase I evaluation, the dose limiting toxicity 
of cabazitaxel observed at 25 mg/m2 every 3 weeks was 
grade 4 neutropenia. Common non-hematologic adverse 
events included low grade diarrhea (52%), nausea (40%), 
and vomiting (16%). Preliminary evidence of antitumor Cabazitaxel for the treatment of CRPC
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activity was observed. Three patients achieved partial 
responses including two patients with CRPC, one of 
whom had previously received docetaxel.
Trials in Other solid Tumors
Given the broad spectrum of activity of the taxanes, 
there  is  significant  interest  in  exploring  cabazi-
taxel for the treatment of a variety of malignancies. 
  Preclinical studies have demonstrated the antitumor 
activity of cabazitaxel in head and neck squamous cell 
  carcinoma.11 Furthermore, early results from breast 
cancer clinical trials have yielded promising results. 
In a phase II multi-center open label trial, patients 
with  breast  cancer  were  treated  with  cabazitaxel 
20 mg/m2 intravenously every three weeks (subse-
quently titrated up to 25 mg/m2 in patients not expe-
riencing adverse events during cycle #1).12 Despite 
the  low  overall  response  rate  (14%),  the  median 
response duration was 7.6 months in this heavily pre-
treated population and 2 patients achieved   complete 
responses. Treatment  was  generally  well  tolerated; 
grade 3/4 anemia and thrombocytopenia were uncom-
mon, and despite high rates of neutropenia, neutro-
penic fevers were rare (3% of patients).
Villanueva  and  colleagues  reported  a  phase  I/II 
dose-escalating study of cabazitaxel with capecitabine 
in patients with metastatic breast cancer progressing 
after anthracycline and taxane treatment.13 Using a 
3 + 3 dose escalation design, cabazitaxel was given 
intravenously at 20 mg/m2 on day 1, and capecitabine 
orally at 825 mg/m2 twice daily from days 1–14, in 
21 day cycles. The PK analysis did not reveal any 
drug-drug  interaction.  The  maximal  tolerated  dose 
(MTD) determined was cabazitaxel at 20 mg/m2, and 
capecitabine 1000 mg/m2. An additional 18 patients, 
with a total of 21 patients, were treated at the MTD 
for the phase II evaluation.
In the phase II evaluation, planned therapy was 
generally  delivered,  with  the  median  relative  dose 
intensity (actual/planned dose intensity) at 0.97 for 
cabazitaxel  and  0.89  for  capecitabine.  Antitumor 
activity was observed, with an overall response rate 
was 23.8% (1 CR, 4 PR). Rates of hematologic tox-
icity were similar to cabazitaxel monotherapy, with 
57.1% of the patients experienced grade 3–4 neutro-
penia, and one reported case of grade 3–4 anemia.
phase 3 clinical experience:  
TROpIc Trial
Given the promising results in the small cohort of patients 
with CRPC in the phase I trial of cabazitaxel, rather than 
proceeding with a phase II study, a strategic decision was 
made to initiate a randomized, multicenter, multinational, 
phase 3 trial (EFC6193; TROPIC) to compare cabazi-
taxel with mitoxantrone in patients with CRPC who had 
progressed  despite  docetaxel-based  chemotherapy.14 
Patients were   randomly assigned to receive either caba-
zitaxel 25 mg/m2   intravenously over 1 hour or mitoxan-
trone 12 mg/m2 intravenously over 15–30 minutes on 
day 1 of each 21-day cycle, with prednisone 10 mg daily. 
Table 1. Pharmacodynamics and kinetics of Cabazitaxel.15
pharmacodynamics/kinetics Value
Protein binding 89% to 92% (serum albumin and lipoproteins)
extensively hepatic (.95%): 
  CYP3A4/5 (80%–90%) 
  CYP2C8 (minor)
Use in renal impairment Minimally excreted in urine 
Mild renal impairment does not affect pharmacokinetics (30 ml/min ,CrCl  
,80 ml/min) 
No data is available in patients with severe renal impairment (CrCl ,30 ml/min)
Use in hepatic impairment No formal trials in patients with hepatic impairment have been conducted. 
Given cabazitaxel is extensively metabolized in the liver, hepatic impairment  
is likely to increase the cabazitaxel concentrations
Half-life elimination Terminal: 95 hours
excretion Feces (76% metabolites) 
Urine (∼4%)
Drug interaction Strong CYP3A inducers or inhibitors are expected to affect the pharmacokinetics  
of cabazitaxelTsao et al
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Premedication, consisting of single intravenous doses of 
an antihistamine, corticosteroid (dexamethasone 8 mg or 
equivalent), and histamine H2-antagonist, was admin-
istered 30 minutes prior to cabazitaxel administration, 
while anti-emetic prophylaxis was given at physicians’ 
discretion. A maximum of 10 cycles of treatment were 
allowed, mainly due to the risk of mitoxantrone-induced 
cardiotoxicity. Patients did not receive prophylactic first-
cycle granulocyte colony stimulating factor, but could 
receive growth factors with subsequent cycles if pro-
longed neutropenia was encountered. The primary end-
point of the study was overall survival.
Seven  hundred  and  fifty-five  patients  were 
  randomized. While 371 of the patients in each arm 
received the intended treatment, more patients receiv-
ing cabazitaxel completed the full treatment course 
compared  to  patients  receiving  mitoxantrone.  The 
baseline characteristics and treatment history of the 
two groups were similar. Of note, during the conduct of 
the trial, the protocol was amended to exclude patients 
previously treated with a cumulative docetaxel dose 
lower than 225 mg/m² to increase the likelihood of 
enrolling a true “docetaxel-refractory” population.
The adverse events observed in the TROPIC trial 
are detailed in Figures 1 and 2. Adverse events with 
cabazitaxel  included  neutropenia  (94%),    anemia 
(97%)  and  thrombocytopenia  (47%).  Notably, 
grade $3 neutropenia occurred in 81.7% of patients 
and  8%  experienced  neutropenic  fever.  The  most 
common non-hematologic toxicities observed in the 
cabazitaxel arm included diarrhea (47%) and fatigue 
(37%). Only 14% of patients treated with cabazitaxel 
experience any grade peripheral neuropathy.
At median follow-up of 12.8 months, an improve-
ment in overall survival was demonstrated for patients 
receiving  cabazitaxel  compared  with  mitoxantrone 
(15.1 month vs. 12.7 months, HR−0.70, P , 0.0001). 
Secondary  outcomes  that  also  favored  treatment 
with  cabazitaxel  over  mitoxantrane  included  pro-
gression-free  survival  (2.8  vs.  1.4  months),  tumor 
response (14.4 vs. 4.4%, P = 0.0005), PSA response 
(39.2%  vs.  17.8%,  P  =  0.0002),  time  to  tumor 
  progression (8.8 vs. 5.4 months, P , 0.0001), and time 
to PSA progression (6.4 vs. 3.1 months, P = 0.001). 
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Figure 1. Hematologic adverse effects of cabazitaxel.14
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Figure 2. Non-hematologic adverse effects of cabazitaxel.14Cabazitaxel for the treatment of CRPC
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Table 2. Ongoing clinical trials evaluating cabazitaxel.16
Trial name Trial enrollment primary 
endpoint
secondary 
endpoint
primary  
completion date
Sanofi-Aventis 
(NCT01254279)
evaluation of early  
access cabazitaxel  
in docetaxel treated  
CRPC
808 early  
cabazitaxel  
access
Safety December 2015
Sanofi-Aventis 
(NCT01001221)
Phase I: Cabazitaxel  
and gemcitabine- 
with midazolam  
(dose escalation, 
pharmacokinetics,  
and safety)
30 DLT 
tumor activity
TTP 
ORR 
DR 
Safety 
PK
June 2013
Sanofi-Aventis 
(NCT00925743)
Phase I/II: Cabazitaxel  
and cisplatin
30 DLT TTP 
DR 
ORR
September 2010
Sanofi-Aventis 
(NCT01140607)
Phase I: Cabazitaxel  
in liver impairment
75 DLT Safety 
Pharmacokinetics
May 2012
Sanofi-Aventis 
(NCT01087021)
Phase I: Cabazitaxel  
on the QTc interval in  
cancer patients
45 Change from 
baseline cQT
eCG 
Plasma concentrations 
Clinical safety 
HR, QT
June 2011
Sanofi-Aventis 
(NCT01308580)
Phase III: Cabazitaxel  
at 20 mg/m² compared  
to 25 mg/m² with  
prednisone for the  
treatment of metastatic 
castration resistant  
prostate cancer
1200 OS  
(noninferiority)
PFS 
PSA progression 
Pain progression  
Tumor response 
PSA response 
Pain response 
Health related QOL 
Pharmacokinetics
Sep 2017
Sanofi-Aventis 
(NCT01308567)
Phase III: Cabazitaxel  
25 mg/m² vs.  
cabazitaxel 20 mg/m²  
vs. docetaxel 75 mg/m²  
in metastatic CRPC not  
previously treated with  
chemotherapy
1170 OS PFS 
Tumor PFS 
PSA PFS 
Pain progression  
Tumor response 
PSA response 
Pain PFS 
Health related QOL 
Pharmacokinetics 
Time to SRe 
Pain response
Jan 2016
Abbreviations: cQT, corrected QT interval; DLT, dose limiting toxicity; DR, duration of response; eCG, electrocardiogram; HR, heart rate; ORR, overall 
response rate; OS, overall survival; PFS, progression free survival; PSA, prostate specific antigen; QOL, quality of life; SRE, skeletal related event;   
TTP, time to progression.
  However, pain control and time to pain progression 
were similar among the two treatment arms.
place in Therapy
On June, 17th 2010, cabazitaxel, co-administered with 
prednisone, was approved by the FDA for the treat-
ment  of  patients  with  metastatic  CRPC  previously 
treated with a docetaxel-containing treatment regimen. 
Cabazitaxel is the first cytotoxic agent to demonstrate a 
  survival benefit in patients with CRPC previously treated 
with   docetaxel. Given the risk of severe   neutropenia and 
febrile neutropenia with this agent, prophylactic growth 
factors are generally administered in clinical practice.
Future Directions
Multiple  clinical  trials  exploring  cabazitaxel  are 
ongoing (Table 2). Two studies will further investi-
gate the pharmacology of cabazitaxel: NCT01140607 
will explore the feasibility of cabazitaxel use in liver 
impairment,  while  NCT01087021  will  assess  the Tsao et al
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impact of cabazitaxel on the QTc interval in cancer 
patients.  Given  the  hematologic  toxicities  demon-
strated in TROPIC, a non-inferiority study compar-
ing cabazitaxel at 20 mg/m2 vs. 25 mg/m2 is currently 
under clinical testing (NCT01308567). Based on the 
demonstrated activity of cabazitaxel in patients with 
docetaxel-refractory disease, the value of moving this 
agent earlier in the course of therapy warrants fur-
ther investigation, and a randomized phase III trial 
of docetaxel compared with two doses of cabazitaxel 
is being planned (NCT01308567). To assess the effi-
cacy and feasibility of combining cabazitaxel with 
other cytotoxic agents, two phase I trials have already 
begun  (NCT00925743:  Cisplatin,  NCT01001221: 
Gemcitabine). In addition, preclinical studies to eval-
uate potential synergy with existing and novel hor-
monal therapies are planned. With the FDA approval 
of additional novel agents for the treatment of CRPC 
(eg, abiraterone, provenge), questions regarding opti-
mal  sequencing  of  drugs,  and  potential  non-cross 
resistance, have emerged which are ripe for clinical 
investigation.
conclusion
The armamentarium for the treatment of patients 
with CRPC is rapidly expanding. In the past year, 
three  novel  agents  with  distinct  mechanisms  of 
action  including  cabazitaxel,  abiraterone,  and 
sipuleucel-T, have demonstrated improvements in 
survival  in  randomized  trials.  Additional  agents 
in  late  stage  clinical  trials  have  already  demon-
strated promising results and additional therapeutic 
options are expected in the near future. The next 
challenge in the management of men with CRPC 
will be to determine the optimal sequence of admin-
istration of these agents, as well as explore rationale 
combinations.
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